[Skip to Content]
[Skip to Content Landing]

Prevalence and Trends in Suicidal Behavior Among US Military Veterans During the COVID-19 Pandemic

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  What is the population-based burden of the COVID-19 pandemic on suicidal behavior among US military veterans?

Finding  In this cohort study of 3078 US military veterans, rates of suicide ideation and suicide attempts did not significantly increase from prepandemic to peripandemic at the population level. However, a small proportion of veterans (2.6%) developed new-onset suicide ideation during the pandemic.

Meaning  These results suggest that despite grim forecasts about the COVID-19 pandemic possibly creating a perfect storm for suicidal behavior, the prevalence of suicidality did not appear to increase among military veterans nearly 10 months into the pandemic.

Abstract

Importance  The COVID-19 pandemic has raised considerable concerns about increased risk for suicidal behavior among US military veterans, who already had elevated rates of suicide before the pandemic.

Objective  To examine longitudinal changes in suicidal behavior from before the COVID-19 pandemic to nearly 10 months into the pandemic and identify risk factors and COVID-related variables associated with new-onset suicide ideation (SI).

Design, Setting, and Participants  This population-based prospective cohort study used data from the first and second wave of the National Health and Resilience in Veterans Study, conducted from November 18, 2019, to December 19, 2020. Median dates of data collection for the prepandemic and peripandemic assessments were November 21, 2019, and November 14, 2020, nearly 10 months after the start of the COVID-19 public health emergency in the US. A total of 3078 US military veterans aged 22 to 99 years were included in the study.

Main Outcomes and Measures  Past-year SI and suicide attempts.

Results  In this cohort study of 3078 US veterans (mean [SD] age, 63.2 [14.7] years; 91.6% men; 79.3% non-Hispanic White veterans, 10.3% non-Hispanic Black veterans, and 6.0% Hispanic veterans), 233 (7.8%) reported past-year SI, and 8 (0.3%) reported suicide attempts at the peripandemic assessment. Past-year SI decreased from 10.6% prepandemic (95% CI, 9.6%-11.8%) to 7.8% peripandemic (95% CI, 6.9%-8.8%). A total of 82 veterans (2.6%) developed new-onset SI over the follow-up period. After adjusting for sociodemographic and military characteristics, the strongest risk factors and COVID-19-related variables for new-onset SI were low social support (odds ratio [OR], 2.77; 95% CI, 1.46-5.28), suicide attempt history (OR, 6.31; 95% CI, 2.71-14.67), lifetime posttraumatic stress disorder and/or depression (OR, 2.25; 95% CI, 1.16-4.35), past-year alcohol use disorder severity (OR, 1.06; 95% CI, 1.01-1.12), COVID-19 infection (OR, 2.41; 95% CI, 1.41-5.01), and worsening of social relationships during the pandemic (OR, 1.47; 95% CI, 1.16-1.88).

Conclusions and Relevance  The results of this cohort study suggest that despite grim forecasts that the COVID-19 pandemic would exacerbate suicidality among US military veterans, the rate of SI decreased at the population level nearly 10 months into the pandemic. Veterans who were infected with COVID-19 were more than twice as likely to report SI, which suggests the need for future research to examine the potential link between COVID-19 infection and suicidal behavior.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: June 27, 2021.

Published Online: August 25, 2021. doi:10.1001/jamapsychiatry.2021.2332

Correction: This article was corrected on October 6, 2021, to fix a sentence in the second paragraph of the Discussion that had erroneously begun with “Third” instead of “Fourth.”

Corresponding Author: Brandon Nichter, PhD, Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 (bnichter@ucsd.edu).

Author Contributions: Dr Pietrzak had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Nichter, Hill, Kline, Norman, Southwick, Pietrzak.

Acquisition, analysis, or interpretation of data: Nichter, Hill, Na, Krystal, Pietrzak.

Drafting of the manuscript: Nichter, Pietrzak.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Nichter, Pietrzak.

Obtained funding: Krystal, Pietrzak.

Administrative, technical, or material support: Krystal, Pietrzak.

Supervision: Southwick, Pietrzak.

Conflict of Interest Disclosures: Dr Southwick reported receiving financial support from the Glenn H. Greenberg Endowed Professorship of Psychiatry, PTSD, and Resilience, Yale University School of Medicine. Dr Krystal reported being a scientific adviser to Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc, Cadent Therapeutics (Clinical Advisory Board), PsychoGenics, Inc, Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, and Lohocla Research Corporation. Dr Krystal reported owning stock and/or stock options in Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc, BlackThorn Therapeutics, Inc, and Terran Biosciences, Inc. Dr Krystal reported receiving less than $10 000 in income (consulting fees) per year from AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Boehringer Ingelheim International, Concert Pharmaceuticals, Inc, Epiodyne, Inc, Heptares Therapeutics, Limited (UK), Janssen Research & Development, L.E.K. Consulting, Otsuka America Pharmaceutical, Inc, Perception Neuroscience Holdings, Inc, Spring Care, Inc, Sunovion Pharmaceuticals, Inc, Takeda Industries, and Taisho Pharmaceutical Co, Ltd. Dr Krystal reported receiving income of greater than $10 000 per year from Biological Psychiatry as an editor. Dr Krystal reported receiving the drug Saracatinib for use in research studies from AstraZeneca and Mavoglurant from Novartis for research related to the National Institute on Alcohol Abuse and Alcoholism grant “Center for Translational Neuroscience of Alcoholism from AstraZeneca Pharmaceuticals.” Dr Krystal reported having the following patents: (1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent 5447948; September 5, 1995; (2) Coric V, Krystal JH, Sanacora G. Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent 8778979 B2. July 15, 2014. US Patent Application No. 15/695164; filing date, September 5, 2017; (3) Charney D, Krystal JH, Manji H, Matthew S, Zarate C. Intranasal Administration of Ketamine to Treat Depression. US application 14/197767 filed on March 5, 2014; US Application or Patent Cooperation Treaty International Application 14/306382 filed on June 17, 2014; (4) Zarate C, Charney DS, Manji HK, Mathew SJ, Krystal JH, Department of Veterans Affairs. Methods for Treating Suicidal Ideation, Patent Application 14/197.767 filed on March 5, 2014, by Yale University Office of Cooperative Research; (5) Arias A, Petrakis I, Krystal JH. Composition and methods to treat addiction. Provisional Use Patent Application 61/973/961 filed on April 2, 2014, by Yale University Office of Cooperative Research; (6) Chekroud A, Gueorguieva R, Krystal JH. Treatment Selection for Major Depressive Disorder, filed on June 3, 2016, USPTO docket Y0087.70116US00. Provisional patent submission by Yale University; (7) Gihyun Y, Petrakis I, Krystal JH. Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. US Provisional Patent Application 62/444552, filed on January 10, 2017, by Yale University Office of Cooperative Research OCR 7088 US01; and (8) Abdallah C, Krystal JH, Duman R, Sanacora G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. US Provisional Patent Application 62/719935 filed on August 20, 2018, by Yale University Office of Cooperative Research OCR 7451 US01. Dr Krystal reported receiving provision of drug from Cerevel and Novartis; stock options from Biohaven Pharmaceuticals, RBNC, Sage, Epivario, Terran, Atai, and Spring Care; patent royalties from Janssen Pharmaceuticals; and personal fees from Biogen, Neurocrine, Takeda, Jazz, Aptinyx, Bionomics, Compass, Concert, Epiodyne, Sunovion, Taisho, BioXcel, Eisai, Psychogenics, Greenwich Biosciences, and Boehringer Ingelheim for advising on clinical trials. In addition, Dr Krystal reported having patent No. 8,778,979 with royalties paid from Biohaven for Use of Glutamate Modulating Agents in the Treatment of Mental Disorders, patent 9,592,207 with royalties paid from Janssen Intranasal for Administration of Ketamine to Treat Depression, and patent 15,379,013 with royalties paid from Janssen Methods for Treating Suicidal Ideation outside the submitted work. Dr Norman reported receiving grants from the Department of Defense, the US Department of Veterans Affairs, and Patient-Centered Outcomes Research Institute and personal fees from Elsevier Press and UptoDate outside the submitted work. No other disclosures were reported.

Funding/Support: The National Health and Resilience in Veterans Study was supported by the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the veterans who participated in this study.

References
1.
Centers for Disease Control and Prevention. COVID-19 data tracker. Accessed May 17, 2021. https://covid.cdc.gov/covid-data-tracker/
2.
World Health Organization. Policy Brief: COVID-19 and the Need for Action on Mental Health. World Health Organization; 2020.
3.
Wasserman  IM .  The impact of epidemic, war, prohibition and media on suicide: United States, 1910-1920.   Suicide Life Threat Behav. 1992;22(2):240-254. doi:10.1111/j.1943-278X.1992.tb00231.xPubMedGoogle Scholar
4.
Yip  PS , Cheung  YT , Chau  PH , Law  YW .  The impact of epidemic outbreak: the case of severe acute respiratory syndrome (SARS) and suicide among older adults in Hong Kong.   Crisis. 2010;31(2):86-92. doi:10.1027/0227-5910/a000015 PubMedGoogle ScholarCrossref
5.
Reger  MA , Stanley  IH , Joiner  TE .  Suicide mortality and coronavirus disease 2019-a perfect storm?   JAMA Psychiatry. 2020;77(11):1093-1094. doi:10.1001/jamapsychiatry.2020.1060 PubMedGoogle ScholarCrossref
6.
Czeisler  MÉ , Lane  RI , Wiley  JF , Czeisler  CA , Howard  ME , Rajaratnam  SMW .  Follow-up survey of US adult reports of mental health, substance use, and suicidal ideation during the COVID-19 pandemic, September 2020.   JAMA Netw Open. 2021;4(2):e2037665. doi:10.1001/jamanetworkopen.2020.37665 PubMedGoogle Scholar
7.
Weiner  J , Richmond  TS , Conigliaro  J , Wiebe  DJ .  Military veteran mortality following a survived suicide attempt.   BMC Public Health. 2011;11(1):374. doi:10.1186/1471-2458-11-374 PubMedGoogle ScholarCrossref
8.
Kuwert  P , Knaevelsrud  C , Pietrzak  RH .  Loneliness among older veterans in the United States: results from the National Health and Resilience in Veterans Study.   Am J Geriatr Psychiatry. 2014;22(6):564-569. doi:10.1016/j.jagp.2013.02.013 PubMedGoogle ScholarCrossref
9.
Nichter  B , Norman  S , Haller  M , Pietrzak  RH .  Psychological burden of PTSD, depression, and their comorbidity in the U.S. veteran population: suicidality, functioning, and service utilization.   J Affect Disord. 2019;256:633-640. doi:10.1016/j.jad.2019.06.072 PubMedGoogle ScholarCrossref
10.
United States Department of Veterans Affairs.  2019 National Veteran Suicide Prevention Annual Report. US Department of Health and Human Services; 2020.
11.
Hoerster  KD , Lehavot  K , Simpson  T , McFall  M , Reiber  G , Nelson  KM .  Health and health behavior differences: US military, veteran, and civilian men.   Am J Prev Med. 2012;43(5):483-489. doi:10.1016/j.amepre.2012.07.029 PubMedGoogle ScholarCrossref
12.
Nock  MK , Deming  CA , Fullerton  CS ,  et al.  Suicide among soldiers: a review of psychosocial risk and protective factors.   Psychiatry. 2013;76(2):97-125. doi:10.1521/psyc.2013.76.2.97 PubMedGoogle ScholarCrossref
13.
Bryan  CJ , Bryan  AO , Baker  JC .  Associations among state-level physical distancing measures and suicidal thoughts and behaviors among US adults during the early COVID-19 pandemic.   Suicide Life Threat Behav. 2020;50(6):1223-1229. doi:10.1111/sltb.12653 PubMedGoogle ScholarCrossref
14.
Tsai  J , Schick  V , Hernandez  B , Pietrzak  RH .  Is homelessness a traumatic event? results from the 2019-2020 National Health and Resilience in Veterans Study.   Depress Anxiety. 2020;37(11):1137-1145. doi:10.1002/da.23098 PubMedGoogle ScholarCrossref
15.
US Census Bureau. The American Community Survey. Accessed January 2021. https://www2.census.gov/programs-surveys/acs/methodology/questionnaires/2019/quest19.pdf
16.
Osman  A , Bagge  CL , Gutierrez  PM , Konick  LC , Kopper  BA , Barrios  FX .  The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples.   Assessment. 2001;8(4):443-454. doi:10.1177/107319110100800409 PubMedGoogle ScholarCrossref
17.
Blevins  CA , Weathers  FW , Davis  MT , Witte  TK , Domino  JL .  The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation.   J Trauma Stress. 2015;28(6):489-498. doi:10.1002/jts.22059 PubMedGoogle ScholarCrossref
18.
Weathers  F , Blake  D , Schnurr  P , Kaloupek  D , Marx  B , Keane  T . Life Events Checklist for DSM-5 (LEC-5). National Center for PTSD; 2018.
19.
Sheehan  D . The Mini International Neuropsychiatric Interview. Harm Research Institute; 2016. Accessed July 27, 2021. https://harmresearch.org/index.php/mini-international-neuropsychiatric-interview-mini
20.
Bastien  CH , Vallières  A , Morin  CM .  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.   Sleep Med. 2001;2(4):297-307. doi:10.1016/S1389-9457(00)00065-4 PubMedGoogle ScholarCrossref
21.
Finkelhor  D , Shattuck  A , Turner  H , Hamby  S .  A revised inventory of adverse childhood experiences.   Child Abuse Negl. 2015;48:13-21. doi:10.1016/j.chiabu.2015.07.011 PubMedGoogle ScholarCrossref
22.
Saunders  JB , Aasland  OG , Babor  TF , de la Fuente  JR , Grant  M .  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II.   Addiction. 1993;88(6):791-804. doi:10.1111/j.1360-0443.1993.tb02093.x PubMedGoogle ScholarCrossref
23.
Steinberg  L , Sharp  C , Stanford  MS , Tharp  AT .  New tricks for an old measure: the development of the Barratt Impulsiveness Scale-Brief (BIS-Brief).   Psychol Assess. 2013;25(1):216-226. doi:10.1037/a0030550 PubMedGoogle ScholarCrossref
24.
Hughes  ME , Waite  LJ , Hawkley  LC , Cacioppo  JT .  A short scale for measuring loneliness in large surveys: results from two population-based studies.   Res Aging. 2004;26(6):655-672. doi:10.1177/0164027504268574 PubMedGoogle ScholarCrossref
25.
Sherbourne  CD , Stewart  AL .  The MOS social support survey.   Soc Sci Med. 1991;32(6):705-714. doi:10.1016/0277-9536(91)90150-B PubMedGoogle ScholarCrossref
26.
Tiet  QQ , Leyva  YE , Moos  RH , Frayne  SM , Osterberg  L , Smith  B .  Screen of drug use: diagnostic accuracy of a new brief tool for primary care.   JAMA Intern Med. 2015;175(8):1371-1377. doi:10.1001/jamainternmed.2015.2438 PubMedGoogle ScholarCrossref
27.
Nikolaidis  A , Paksarian  D , Alexander  L ,  et al.  The Coronavirus Health and Impact Survey (CRISIS) reveals reproducible correlates of pandemic-related mood states across the Atlantic.   Sci Rep. 2021;11(1):8139. doi:10.1038/s41598-021-87270-3PubMedGoogle ScholarCrossref
28.
Tonidandel  S , LeBreton  JM .  Relative importance analysis: a useful supplement to regression analysis.   J Bus Psychol. 2011;26(1):1-9. doi:10.1007/s10869-010-9204-3 Google ScholarCrossref
29.
Pierce  M , Hope  H , Ford  T ,  et al.  Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population.   Lancet Psychiatry. 2020;7(10):883-892. doi:10.1016/S2215-0366(20)30308-4 PubMedGoogle ScholarCrossref
30.
Han  B , Compton  WM , Gfroerer  J , McKeon  R .  Prevalence and correlates of past 12-month suicide attempt among adults with past-year suicidal ideation in the United States.   J Clin Psychiatry. 2015;76(3):295-302. doi:10.4088/JCP.14m09287 PubMedGoogle ScholarCrossref
31.
Centers for Disease Control and Prevention. Monthly provisional counts of deaths by select causes, 2020-2021. Accessed March 15, 2021. https://data.cdc.gov/NCHS/Monthly-Counts-of-Deaths-by-Select-Causes-2020-202/9dzk-mvmi
32.
Bruine de Bruin  W .  Age differences in COVID-19 risk perceptions and mental health: evidence from a national US survey conducted in March 2020.   J Gerontol B Psychol Sci Soc Sci. 2021;76(2):e24-e29. doi:10.1093/geronb/gbaa074PubMedGoogle ScholarCrossref
33.
Vahia  IV , Blazer  DG , Smith  GS ,  et al.  COVID-19, mental health and aging: a need for new knowledge to bridge science and service.   Am J Geriatr Psychiatry. 2020;28(7):695-697. doi:10.1016/j.jagp.2020.03.007 PubMedGoogle ScholarCrossref
34.
Tsai  J , Mota  NP , Southwick  SM , Pietrzak  RH .  What doesn’t kill you makes you stronger: a national study of U.S. military veterans.   J Affect Disord. 2016;189:269-271. doi:10.1016/j.jad.2015.08.076 PubMedGoogle ScholarCrossref
35.
Pietrzak  RH , Tsai  J , Southwick  SM .  Association of symptoms of posttraumatic stress disorder with posttraumatic psychological growth among US veterans during the COVID-19 pandemic.   JAMA Netw Open. 2021;4(4):e214972. doi:10.1001/jamanetworkopen.2021.4972 PubMedGoogle Scholar
36.
Kowalski  RM , Carroll  H , Britt  J .  Finding the silver lining in the COVID-19 crisis.   J Health Psychol. 2021;135910532199908(March):1359105321999088. doi:10.1177/1359105321999088PubMedGoogle Scholar
37.
Gordon  KH , Bresin  K , Dombeck  J , Routledge  C , Wonderlich  JA .  The impact of the 2009 Red River flood on interpersonal risk factors for suicide.   Crisis. 2011;32(1):52-55. doi:10.1027/0227-5910/a000051 PubMedGoogle ScholarCrossref
38.
Lester  D .  The effect of war on suicide rates: a study of France from 1826 to 1913.   Eur Arch Psychiatry Clin Neurosci. 1993;242(4):248-249. doi:10.1007/BF02189971 PubMedGoogle ScholarCrossref
39.
Joiner  TE , Hollar  D , Van Orden  K .  On Buckeyes, Gators, Super Bowl Sunday, and the Miracle on Ice: “pulling together” is associated with lower suicide rates.   J Soc Clin Psychol. 2006;25(2):179-195. doi:10.1521/jscp.2006.25.2.179 Google ScholarCrossref
40.
C-SPAN. President Trump roundtable discussion on donating plasma. July 30, 2020. Accessed March 5, 2021. https://www.c-span.org/video/?474383-1/president-trump-roundtable-discussion-donating-plasma
41.
Joiner  TE , Van Orden  KA , Witte  TK , Rudd  MD .  The Interpersonal Theory of Suicide: Guidance for Working with Suicidal Clients. American Psychological Association; 2009. doi:10.1037/11869-000
42.
Pietrzak  RH , Goldstein  MB , Malley  JC , Rivers  AJ , Johnson  DC , Southwick  SM .  Risk and protective factors associated with suicidal ideation in veterans of Operations Enduring Freedom and Iraqi Freedom.   J Affect Disord. 2010;123(1-3):102-107. doi:10.1016/j.jad.2009.08.001 PubMedGoogle ScholarCrossref
43.
Franklin  JC , Ribeiro  JD , Fox  KR ,  et al.  Risk factors for suicidal thoughts and behaviors: a meta-analysis of 50 years of research.   Psychol Bull. 2017;143(2):187-232. doi:10.1037/bul0000084 PubMedGoogle ScholarCrossref
44.
Lemaire  CM , Graham  DP .  Factors associated with suicidal ideation in OEF/OIF veterans.   J Affect Disord. 2011;130(1-2):231-238. doi:10.1016/j.jad.2010.10.021 PubMedGoogle ScholarCrossref
45.
Nichter  B , Stein  MB , Norman  SB ,  et al.  Prevalence, correlates, and treatment of suicidal behavior in US Military veterans: results from the 2019–2020 National Health and Resilience in Veterans Study.   J Clin Psychiatry. 2021;82(00):20m13714.Google Scholar
46.
Nichter  B , Hill  M , Norman  S , Haller  M , Pietrzak  RH .  Associations of childhood abuse and combat exposure with suicidal ideation and suicide attempt in US military veterans: a nationally representative study.   J Affect Disord. 2020;276:1102-1108. doi:10.1016/j.jad.2020.07.120 PubMedGoogle ScholarCrossref
47.
Nichter  B , Norman  SB , Maguen  S , Pietrzak  RH .  Moral injury and suicidal behavior among US combat veterans: results from the 2019-2020 National Health and Resilience in Veterans Study.   Depress Anxiety. 2021;38(6):606-614. doi:10.1002/da.23145PubMedGoogle ScholarCrossref
48.
Fitzpatrick  KM , Harris  C , Drawve  G .  How bad is it? suicidality in the middle of the COVID-19 pandemic.   Suicide Life Threat Behav. 2020;50(6):1241-1249. doi:10.1111/sltb.12655 PubMedGoogle ScholarCrossref
49.
van de Mortal  TF, .  Faking it: social desirability response bias in self-report research.   Aust J Adv Nurs. 2008;25(4):40-48.Google Scholar
50.
Nichter  B , Hill  M , Norman  S , Haller  M , Pietrzak  RH .  Mental health treatment utilization among US military veterans with suicidal ideation: results from the National Health and Resilience in Veterans Study.   J Psychiatr Res. 2020;130:61-67. doi:10.1016/j.jpsychires.2020.07.004PubMedGoogle ScholarCrossref
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close